// App-Quantinova.ai

TPS8551 : GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.

Researchers

Presenter

  • Adam D. Cohen

Principal Investigators

  • Suzanne Trudel

  • Peter A. Forsberg

  • Rafael Fonseca

  • Amrita Y. Krishnan

  • Andrew Spencer

  • Jesus G. Berdeja

  • Sarah M. Hamirani

  • Mengsong Li

  • James Cooper

  • Simon J. Harrison

Medical Centers

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • University of Colorado Denver School of Medicine, Aurora, CO

  • Mayo Clinic Arizona, Phoenix, AZ

  • City of Hope, Duarte, CA

  • Alfred Health-Monash University, Melbourne, Australia

  • Sarah Cannon Research Institute, Nashville, TN

  • Genentech, Inc., South San Francisico, CA

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cluster of Differentiation 2AP

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Multicenteric

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT03275103

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved